Dehydration News and Research

Latest Dehydration News and Research

Allos reaches SPA agreement with FDA for FOLOTYN Phase 3 trial in PTCL

Allos Therapeutics, Inc. today announced that the Company has reached agreement with the U.S. Food and Drug Administration (FDA) under its Special Protocol Assessment (SPA) process for the design of the Company's Phase 3 clinical trial of FOLOTYN® (pralatrexate injection) in patients with previously undiagnosed peripheral T-cell lymphoma (PTCL).

4 Mar 2011

OneWorld Health receives FDA clearance for iOWH032 phase 1 trials to treat secretory diarrhea

The Institute for OneWorld Health (iOWH) announced a major milestone in the fight against cholera. The Food and Drug Administration (FDA) granted iOWH permission to begin phase 1 trials for iOWH032, a drug to treat secretory diarrhea. This is the first submission of an Investigational New Drug application for a completely new chemical entity by a non-profit of this size to receive such rapid FDA clearance, and it could be the first synthetic drug of its kind for diarrheal diseases.

2 Mar 2011

Treat discomfort not fever say the new pediatric guidelines

According to a new report from the American Academy of Pediatrics (AAP), fevers alone are not a cause for intervention in children. Dr. Janice Sullivan, the lead author of the report says, “The focus should be on comfort and not on absolute temperature.” That’s because fever can be help fight illness, by slowing down the reproduction of bacteria and viruses or stimulating the body’s immune response she explains. “That’s a benefit of fever…and may shorten the time that your child remains ill,” she adds.

28 Feb 2011

Genentech granted FDA hearing on Avastin for metastatic breast cancer

Genentech, a member of the Roche Group, today announced the U.S. Food and Drug Administration (FDA) has granted a hearing to allow the company the opportunity to present its views on why Avastin® (bevacizumab) should remain FDA-approved for metastatic breast cancer (mBC). The FDA has scheduled the hearing for June 28 to 29, 2011.

25 Feb 2011

Bangladesh cholera vaccine trial

Bangladesh will conduct the world’s largest clinical trial of an affordable cholera vaccine which could save tens of thousands of lives. The study began Thursday and involves nearly 250,000 people near the capital, Dhaka.

20 Feb 2011

PM Pediatrics launches new location in Bayside, Queens

PM Pediatrics, the preeminent provider of after-hours pediatric urgent care in New York, operating urgent care practices in Nassau, Suffolk and Westchester counties, today announced the launch of its newest location in Bayside, Queens. Beginning Friday, March 11, 2011, the urgent care site, located at 210-31 26th Avenue in the popular Bay Terrace Shopping Center, will open its doors to the community.

17 Feb 2011

Dengue strikes in a “vicious” way in north Qld

According to health authorities a vicious strain of Dengue fever is hospitalising people in far north Queensland. 20 people have been diagnosed with the Type 2 variant of the virus in East Innisfail and another five have Type 4 Dengue. 12 other people are possibly ill with the virus and awaiting laboratory confirmation.

15 Feb 2011

Positive results from Glenmark's crofelemer Phase 2 study in acute watery diarrhea

Napo Pharmaceuticals, Inc. is pleased to announce the positive results of a successfully completed Phase 2 study of crofelemer for the treatment of hospitalized adult patients with mild to moderate acute watery diarrhea conducted by its partner Glenmark Pharmaceuticals Ltd..

14 Feb 2011

Key advance in development of fast, simple test for detection of cholera

With cholera on the rampage in Haiti and almost 40 other countries, scientists are reporting the development of a key advance that could provide a fast, simple test to detect the toxin that causes the disease. The report appears in ACS' journal Bioconjugate Chemistry. Cholera affects more than 200,000 people annually, mainly in developing countries, and causes about 5,000 deaths. Many involve infants, children, and the elderly.

10 Feb 2011

AJN: Nurses and physicians lack knowledge about human trafficking

A report, published in the February issue of the American Journal of Nursing, underscores nurse and physicians' lack of knowledge about the indicators of human trafficking when they encounter a patient who is a victim of trafficking.

8 Feb 2011

Genentech's OCEANS Phase III study of Avastin in platinum-sensitive ovarian cancer meets primary endpoint

Genentech, a member of the Roche Group, announced today that OCEANS, a Phase III study evaluating Avastin® (bevacizumab) in combination with chemotherapy (carboplatin and gemcitabine) followed by continued use of Avastin alone until disease progression in women with previously treated (recurrent), platinum-sensitive ovarian cancer, met its primary endpoint.

8 Feb 2011

Phase II results of VELCADE in patients with aggressive lymphoma published in Journal of Clinical Oncology

Millennium: The Takeda Oncology Company today announced that Phase II results of a clinical trial examining VELCADE (bortezomib) in patients with previously untreated aggressive lymphoma were published in the Journal of Clinical Oncology.

5 Feb 2011

Tips for women to ensure a healthy heart and a healthy vacation

Henrico County based Mondial Assistance, the largest travel insurance provider in the world, and the American Heart Association's (AHA) Mid-Atlantic chapter are teaming up for the 2011 Go Red for Women campaign and as part of the effort are offering these tips for women to ensure a healthy heart and a healthy vacation in 2011. Mondial Assistance is a "Healthy Lifestyle" Partner for this year's campaign.

5 Feb 2011

CVT more common than previously thought, disproportionally affects pregnant women

A rare and often underreported form of stroke that involves veins instead of arteries is more common than previously thought, according to the American Heart Association's first scientific statement on diagnosing and managing cerebral venous thrombosis (CVT).

4 Feb 2011

GATTEX Phase 3 pivotal study reaches primary efficacy endpoint of reducing PN in patients with SBS

NPS Pharmaceuticals, a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced that its Phase 3 pivotal study of GATTEX met the primary efficacy endpoint of reducing parenteral nutrition dependence in patients with adult short bowel syndrome.

31 Jan 2011

Extreme morning sickness drug comes at a price

Women, who suffer from an extreme form of morning sickness called hyperemesis gravidarum (HG), are shelling out $7,000 for a drug not yet approved for use by expectant mums because they are desperate to control their illness. HG leads to severe nausea, dehydration and fatigue and may require hospitalization. It affects up to 3 per cent of pregnant women - about 9,000 per year in Australia. It may lead to termination of the pregnancy.

31 Jan 2011

FOLOTYN Phase 2 peripheral T-cell lymphoma study results published in Journal of Clinical Oncology

Allos Therapeutics, Inc. today announced that the Journal of Clinical Oncology has published data from the Company's pivotal Phase 2 PROPEL study demonstrating clinical activity of FOLOTYN® (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

20 Jan 2011

Living at higher altitudes may increase risk for suicide

Twenty years of mortality data from counties across the United States led to the striking discovery that living at higher altitudes may be a risk factor for suicide, according to a provocative study published online ahead of print in High Altitude Medicine & Biology, a peer-reviewed journal published by Mary Ann Liebert, Inc. The article is attached.

14 Jan 2011

FDA accepts Merck's JANUMET extended-release formulation NDA for type 2 diabetes

Merck today announced that the New Drug Application (NDA) for the Company's investigational extended-release formulation of JANUMET for type 2 diabetes has been accepted for standard review by the U.S. Food and Drug Administration (FDA). The Company is also moving forward as planned with regulatory filings in countries outside the United States.

12 Jan 2011

Haiti teen to undergo open-heart surgery at Montefiore

Mahalia Desruisseaux, M.D., assistant professor of pathology and of medicine at Albert Einstein College of Medicine of Yeshiva University who had traveled to Haiti to assist in the relief effort, identified a serious heart condition. Now, one year later, Ms. Ajuste will undergo open-heart surgery at Montefiore, The University Hospital and Academic Medical Center for Einstein, to correct the defect.

11 Jan 2011

Dehydration News and Research

Latest Dehydration News and Research

Allos reaches SPA agreement with FDA for FOLOTYN Phase 3 trial in PTCL

OneWorld Health receives FDA clearance for iOWH032 phase 1 trials to treat secretory diarrhea

Treat discomfort not fever say the new pediatric guidelines

Genentech granted FDA hearing on Avastin for metastatic breast cancer

Bangladesh cholera vaccine trial

PM Pediatrics launches new location in Bayside, Queens

Dengue strikes in a “vicious” way in north Qld

Positive results from Glenmark's crofelemer Phase 2 study in acute watery diarrhea

Key advance in development of fast, simple test for detection of cholera

AJN: Nurses and physicians lack knowledge about human trafficking

Genentech's OCEANS Phase III study of Avastin in platinum-sensitive ovarian cancer meets primary endpoint

Phase II results of VELCADE in patients with aggressive lymphoma published in Journal of Clinical Oncology

Tips for women to ensure a healthy heart and a healthy vacation

CVT more common than previously thought, disproportionally affects pregnant women

GATTEX Phase 3 pivotal study reaches primary efficacy endpoint of reducing PN in patients with SBS

Extreme morning sickness drug comes at a price

FOLOTYN Phase 2 peripheral T-cell lymphoma study results published in Journal of Clinical Oncology

Living at higher altitudes may increase risk for suicide

FDA accepts Merck's JANUMET extended-release formulation NDA for type 2 diabetes

Haiti teen to undergo open-heart surgery at Montefiore

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Dehydration News and Research

Latest Dehydration News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in